AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in machine learning and wet lab platforms, to discover and develop next-generation antibodies for multiple therapeutic targets in oncology and neuroscience. BigHat will receive an upfront payment of USD 30 million, with the potential for up to USD 325 million in research and development milestone payments, additional commercial milestone payments, and sales royalties.
This collaboration aims to leverage BigHat’s advanced computational and experimental capabilities to enhance AbbVie’s pipeline in the areas of oncology and neuroscience, further solidifying AbbVie’s commitment to innovation in these therapeutic areas.- Flcube.com
